We bring medicines to market, and hold the position for years.
From registration to lifecycle management, our commercial chain runs end to end across more than a hundred markets. The same regulatory backbone carries the portfolio we own and the products we commercialize for partners.
Products in sale
500+
SKUs
2,000+
TABLETS A YEAR
5.2B
CAPSULES A YEAR
700M
Markets licensed
100+
GLOBAL PARTNERS
600+
Decades of category positions held in prescription medicine and in consumer healthcare.
rx
Prescription Medicine
A prescription portfolio weighted toward hard-to-make generics, complex formulations, and value-added products - molecules that take real work to develop and aren't quickly copied. When exclusivity ends, we're ready on Day 1: on shelf the moment the patent clears.
chc
Consumer Healthcare
The CHC portfolio is built household brands - Polopiryna, Ibufen, Ranigast, Xylogel, Biotebal - names families have trusted for decades, with Vitamin D leadership across CEE and CIS. Brand equity like this can't be bought into; it's built over years, which is what makes it hard to displace.
Group’s commentary
“In Poland, one in eight packs sold in pharmacies is ours. In Kazakhstan, we lead the market with 240 products across 12 pharmacotherapeutic groups.”
Multi-regional at the core, worldwide beyond it
Manufacturing anchored in five EU GMP sites in Poland, with Santo in Kazakhstan holding the first EU GMP certification ever granted in Central Asia. From those sites, we sell directly in the markets that form our core, partner with long-term distributors across our broader region, and license to commercial partners worldwide.
PARTNERSHIP models
Our local commercial position across Europe, CIS, and Central Asia is open to partners.
Direct affiliate commercialization
Own brand export distribution
Out-licensing
In-licensing
Strategic partnerships
Hospital tender distribution
Tender capability
Most of our markets buy medicine through public procurement. We win those contracts.
Hospital tendering
Poland runs one of the EU's most price-competitive hospital markets: tenders at the level of individual hospitals, split into per-substance packages. In Kazakhstan, Santo supplies more than a third of the state-funded medicines basket through centralized procurement.
Statutory insurance
Germany's Rabattverträge - multi-year exclusive supply contracts awarded by individual statutory health insurance funds - cover the majority of generic prescriptions in the EU's largest pharma market. We hold contracts across cardiovascular combinations and metabolic therapies, won against the market's biggest players.
Available to partner products
Partner products under in-licensing and distribution agreements get the same tender capability, run by the same teams that win for our own portfolio.
Winning a tender is one thing. Holding it is another: years of exclusive supply under continuous audit, penalties for every stockout, renewal driven by service reliability as much as price. Sustaining a position takes MA holdership, local-language submission capability, manufacturing capacity behind the volume, and decades of relationships with procurement.
It's why most generic producers enter foreign markets through wholesalers - tender execution is a different model: local affiliate, local team, local audit history.
One in three medicine packs used in Polish hospitals comes from us. We are the sole manufacturer of forty-two medicines in the Polish system.
Post Launch
Every product on every market we serve has a team that maintains it.
Group’s commentary
Partners representing 70% of our B2B business rate us 8.18 out of 10.
"Polpharma Group manufactures around 400 million packs of medicines annually. Every third medicine reaching hospitals in Poland and every eighth available in pharmacies comes from our production. In hospitals, these are largely life-saving preparations such as adrenaline or morphine.
Barbara Misiewicz-Jagielak Pricing Strategy and Reimbursement Director
.avif)
